+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 22 Pages
  • August 2023
  • GlobalData
  • ID: 4058171
WEX Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The publisher's summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

WEX Pharmaceuticals Inc (WEX), a subsidiary of CK Life Sciences Int'l, (Holdings) Inc, is a clinical stage biotechnology company. It focuses on the discovery, development, manufacture and commercialization of drugs for pain management. The company is developing a new class of non-opioid analgesics by utilizing its proprietary platform technology TTX (Tetrodotoxin or TTX). TTX is non-peptide neurotoxin, non-addictive alternative to opioids, and a sodium channel blocker. WEX’s clinical candidates include TEC-006, and TTX-CINP-201, which are being studied for the treatment of moderate to severe cancer related pain and neuropathic pain caused by chemotherapy. WEX is headquartered in Vancouver, British Columbia, Canada.

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the publisher's detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • WEX Pharmaceuticals Inc - Key Facts
  • WEX Pharmaceuticals Inc - Key Employees
  • WEX Pharmaceuticals Inc - Key Employee Biographies
  • WEX Pharmaceuticals Inc - Major Products and Services
  • WEX Pharmaceuticals Inc - History
  • WEX Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Company Overview
  • WEX Pharmaceuticals Inc - Business Description
  • WEX Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • WEX Pharmaceuticals Inc - Strengths
  • WEX Pharmaceuticals Inc - Weaknesses
  • WEX Pharmaceuticals Inc - Opportunities
  • WEX Pharmaceuticals Inc - Threats
  • WEX Pharmaceuticals Inc - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • WEX Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • WEX Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • WEX Pharmaceuticals Inc, Recent Deals Summary
Section 4 - Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • WEX Pharmaceuticals Inc, Key Facts
  • WEX Pharmaceuticals Inc, Key Employees
  • WEX Pharmaceuticals Inc, Key Employee Biographies
  • WEX Pharmaceuticals Inc, Major Products and Services
  • WEX Pharmaceuticals Inc, History
  • WEX Pharmaceuticals Inc, Key Competitors
  • WEX Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • WEX Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • WEX Pharmaceuticals Inc, Recent Deals Summary
List of Figures
  • WEX Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • WEX Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Neoleukin Therapeutics Inc
  • IntelGenx Corp
  • EquiTech Corp
  • Altus Formulation Inc
  • PainCeptor Pharma Corp